Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIM NASDAQ:ELVN NASDAQ:GPCR NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/AELVNEnliven Therapeutics$20.85+5.1%$20.61$13.30▼$30.03$1.24B0.93394,504 shs830,394 shsGPCRStructure Therapeutics$19.61+1.2%$19.24$13.22▼$45.37$1.13B-1.89922,092 shs544,304 shsTLRYTilray Brands$1.15+3.6%$0.66$0.35▼$1.95$1.27B1.8576.75 million shs51.16 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%-0.89%ELVNEnliven Therapeutics0.00%+3.12%-5.01%+27.13%-11.91%GPCRStructure Therapeutics0.00%-2.53%+7.33%-20.12%-50.53%TLRYTilray Brands0.00%+11.65%+63.63%+159.95%-39.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/AELVNEnliven Therapeutics2.8371 of 5 stars3.52.00.00.02.44.20.0GPCRStructure Therapeutics2.6298 of 5 stars3.53.00.00.01.91.70.6TLRYTilray Brands2.4385 of 5 stars3.11.00.00.03.21.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 0.00N/AN/AN/AELVNEnliven Therapeutics 3.00Buy$41.2097.60% UpsideGPCRStructure Therapeutics 3.00Buy$75.71286.10% UpsideTLRYTilray Brands 2.20Hold$1.9266.67% UpsideCurrent Analyst Ratings BreakdownLatest ALIM, ELVN, TLRY, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.008/7/2025GPCRStructure TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$92.00 ➝ $90.008/7/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.007/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral7/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.00(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/ATLRYTilray Brands$821.31M1.54$0.14 per share7.96$1.40 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/AELVNEnliven Therapeutics-$89.02M-$2.000.00N/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$1.050.00N/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)TLRYTilray Brands-$2.19B-$2.310.00N/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest ALIM, ELVN, TLRY, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/A7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62ELVNEnliven TherapeuticsN/A32.5832.58GPCRStructure TherapeuticsN/A20.4820.48TLRYTilray Brands0.202.461.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%ELVNEnliven Therapeutics95.08%GPCRStructure Therapeutics91.78%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%ELVNEnliven Therapeutics25.90%GPCRStructure Therapeutics5.60%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableELVNEnliven Therapeutics5059.24 million43.89 millionOptionableGPCRStructure Therapeutics13657.60 million54.37 millionOptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableALIM, ELVN, TLRY, and GPCR HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Trading Up 2.3% - What's Next?August 23 at 4:46 PM | marketbeat.comTilray Brands, Inc. (NASDAQ:TLRY) Given Average Recommendation of "Hold" by AnalystsAugust 23 at 3:41 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Up 3.3% - Here's What HappenedAugust 22 at 1:46 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 3.3% - Time to Sell?August 21 at 3:37 PM | marketbeat.comTilray's High Hopes: The Catalyst Driving Cannabis Stocks...August 21 at 2:09 PM | marketbeat.comTop Cannabis Stocks To Watch Today - August 20thAugust 21 at 1:11 PM | marketbeat.comUnleashing the Spirit of Adventure: Breckenridge Distillery Launches Mountain Shot, a Bold New Mushroom-Infused ElixirAugust 21 at 7:00 AM | globenewswire.comTilray Brands (NASDAQ:TLRY) Trading Down 7.5% - Time to Sell?August 20, 2025 | marketbeat.comCannabis Stocks To Follow Today - August 19thAugust 20, 2025 | marketbeat.comTilray Shares Blazing: What's Behind the 55% Rally This Month?...August 20, 2025 | marketbeat.comIf You'd Invested $1,000 in Tilray Stock 5 Years Ago, Here's How Much You'd Have TodayAugust 20, 2025 | fool.comTilray Brands (NASDAQ:TLRY) Shares Up 9.2% - Time to Buy?August 19, 2025 | marketbeat.comPromising Cannabis Stocks To Add to Your Watchlist - August 18thAugust 19, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Up - Here's WhyAugust 19, 2025 | marketbeat.comTilray Brands (NASDAQ TLRY) Rises Amid NASDAQ Composite Market TrendsAugust 19, 2025 | kalkinemedia.comKPromising Cannabis Stocks To Add to Your Watchlist - August 17thAugust 18, 2025 | marketbeat.comNational Bank of Canada FI Sells 763,247 Shares of Tilray Brands, Inc. $TLRYAugust 18, 2025 | marketbeat.comTilray Brands (TLRY) Boosts Revenue Mix with New Cannabis, Wellness, and Beverage ProductsAugust 17, 2025 | insidermonkey.comCannabis Stocks Worth Watching - August 16thAugust 17, 2025 | marketbeat.comBest Canadian Cannabis Stocks in 2025August 17, 2025 | marijuanastocks.comMTilray Brands (NASDAQ:TLRY) Trading Down 7.2% - Here's What HappenedAugust 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025ALIM, ELVN, TLRY, and GPCR Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Enliven Therapeutics NASDAQ:ELVN$20.85 +1.01 (+5.09%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$20.88 +0.03 (+0.14%) As of 08/22/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Structure Therapeutics NASDAQ:GPCR$19.61 +0.24 (+1.24%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$19.92 +0.32 (+1.61%) As of 08/22/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Tilray Brands NASDAQ:TLRY$1.15 +0.04 (+3.60%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.